Apr 12, 2019 (Analytical Research Cognizance via COMTEX News Network) -- The global Tourette Syndrome Drug market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.This report focuses on Tourette Syndrome Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Tourette Syndrome Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered: Abide Therapeutics Inc Catalyst Pharmaceuticals Inc Neurocrine Biosciences Inc Psyadon Pharmaceuticals Inc Reviva Pharmaceuticals Inc Synchroneuron Inc Teva Pharmaceutical Industries Ltd Therapix Biosciences Ltd
Segment by Regions North America Europe China Japan
Segment by Type AZD-5213 CPP-115 Dutetrabenazine ER Ecopipam Hydrochloride Others
Segment by Application Research Center Hospital Clinic Others
Purchase a copy @ http://www.arcognizance.com/purchase/344652